Literature DB >> 17347697

Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profile.

Leslie Price1, Allan Sniderman, Attila Omerglu, Kevin Lachapelle.   

Abstract

Hypercholesterolemia has been identified as a risk factor for bioprosthetic valvular degeneration, and it has been suggested that statin therapy reduces this risk. The case of a 77-year-old man with low levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B who developed marked LDL-C crystal deposition and a severe foreign body giant cell reaction 21.5 years after aortic bioprosthetic replacement is reported. This observation confirms that cholesterol deposition contributes to bioprosthetic valve degeneration, but that this can occur even in patients with low levels of LDL-C. It suggests that the characteristics of the valve are more critical than the patient's level of LDL-C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347697      PMCID: PMC2647874          DOI: 10.1016/s0828-282x(07)70751-1

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  11 in total

1.  Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves?

Authors:  Tirone E David; Joan Ivanov
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

2.  Calcification resistance with aluminum-ethanol treated porcine aortic valve bioprostheses in juvenile sheep.

Authors:  Matthew F Ogle; Sheila J Kelly; Richard W Bianco; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2003-04       Impact factor: 4.330

3.  Osteopontin is associated with bioprosthetic heart valve calcification in humans.

Authors:  M Shen; P Marie; D Farge; S Carpentier; C De Pollak; M Hott; L Chen; B Martinet; A Carpentier
Journal:  C R Acad Sci III       Date:  1997-01

4.  Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Efficacy and mechanisms.

Authors:  N Vyavahare; D Hirsch; E Lerner; J Z Baskin; F J Schoen; R Bianco; H S Kruth; R Zand; R J Levy
Journal:  Circulation       Date:  1997-01-21       Impact factor: 29.690

5.  Characterization of the immune response to valve bioprostheses and its role in primary tissue failure.

Authors:  P Human; P Zilla
Journal:  Ann Thorac Surg       Date:  2001-05       Impact factor: 4.330

6.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

Authors:  S Joanna Cowell; David E Newby; Robin J Prescott; Peter Bloomfield; John Reid; David B Northridge; Nicholas A Boon
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

7.  Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy.

Authors:  K Eishi; H Ishibashi-Ueda; K Nakano; Y Kosakai; Y Sasako; J Kobayashi; C Yutani
Journal:  J Heart Valve Dis       Date:  1996-11

8.  Time-dependent effect of glutaraldehyde on the tendency to calcify of both autografts and xenografts.

Authors:  K Liao; R W Frater; A LaPietra; G Ciuffo; C F Ilardi; E Seifter
Journal:  Ann Thorac Surg       Date:  1995-08       Impact factor: 4.330

9.  Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement.

Authors:  Georg Nollert; Jessica Miksch; Eckart Kreuzer; Bruno Reichart
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

10.  Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation.

Authors:  Robert Saeid Farivar; Lawrence H Cohn
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.